A controversial trend is emerging in the medical field, and it's time to shed light on this important issue. Despite a lack of clinical guidance, the use of obesity drugs, specifically GLP-1 receptor agonists, in cancer patients is on the rise. This practice raises eyebrows and sparks a crucial conversation about patient safety and the need for evidence-based recommendations.
Let's dive into the details. A recent study revealed that prescriptions for GLP-1 receptor agonists, such as semaglutide and tirzepatide, have increased among cancer patients, even though there's little to no clinical data supporting their safety and efficacy in this specific patient population. The overall prescription rate, though low at 4.1%, has shown a significant upward trend over the past four years, ending at 0.7% in May 2025.
But here's where it gets interesting: the highest prescription rates were observed in patients with obesity-related cancers, namely thyroid, breast, and endometrial cancers. This finding suggests a potential link between obesity and the prescription of these drugs in cancer patients.
Dr. Yuan Lu, from the Yale School of Medicine, emphasizes the lack of robust evidence, stating, "We need future research to explore this issue thoroughly." She highlights the challenge of excluding cancer patients from most clinical trials due to the high costs and lengthy timelines involved.
However, there's a glimmer of hope. Electronic health records (EHR) and claims data, combined with analytical methods, can simulate clinical trial designs, offering a potential solution to examine the benefits and safety of these drugs in cancer patients.
And this is the part most people miss: GLP-1 agonists, while revolutionary in obesity treatment, have received little attention in the context of cancer-specific considerations. The potential for complications, such as drug interactions or cachexia, raises valid concerns about their use in cancer patients.
To investigate current prescribing practices, researchers searched the Epic Cosmos Dataset for adults newly diagnosed with one of 14 cancer types between January 2021 and May 2025. The search identified over 569,000 cancer patients, with 4.1% of them receiving prescriptions for semaglutide or tirzepatide.
The study also revealed that patients receiving these prescriptions were younger, more likely to be female, and had a higher BMI. The prescription rates varied significantly across different cancer types, with the highest rates observed in thyroid cancer patients (10.1%).
The authors emphasize the urgent need for evidence-based recommendations to optimize safety and outcomes, given the rapid adoption of GLP-1 receptor agonists in cancer patients without diabetes.
So, what do you think? Is this trend a step towards innovative cancer treatment, or does it raise more concerns than it solves? Share your thoughts in the comments below!
